Clinical Relevance of +936 C&gt;T VEGFA and c.233C&gt;T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Ballester, Sandra; Pineda, Begoña; Rodrigues, Patrícia; Tormo, Eduardo; Terol, María José; Eroles, Pîlar

doi:10.3390/genes11060686

Cited by 3 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular endothelial growth factor A (VEGFA) is a member of the PDGF/VEGF growth factor family. The angiogenesis process makes a significant contribution to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL), the levels of VEGFA and bFGF being higher in patients than in healthy people ( Ballester et al, 2020 ). Whereas, in our research, VEGFA has a protective role in CLL.…”

Section: Discussionmentioning

confidence: 99%

Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients

et al. 2022

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a type of highly heterogeneous mature B-cell malignancy with various disease courses. Although a multitude of prognostic markers in CLL have been reported, insights into the role of super-enhancer (SE)-related risk indicators in the occurrence and development of CLL are still lacking. A super-enhancer (SE) is a cluster of enhancers involved in cell differentiation and tumorigenesis, and is one of the promising therapeutic targets for cancer therapy in recent years. In our study, the CLL-related super-enhancers in the training database were processed by LASSO-penalized Cox regression analysis to screen a nine-gene prognostic model including TCF7, VEGFA, MNT, GMIP, SLAMF1, TNFRSF25, GRWD1, SLC6AC, and LAG3. The SE-related risk score was further constructed and it was found that the predictive performance with overall survival and time-totreatment (TTT) was satisfactory. Moreover, a high correlation was found between the risk score and already known prognostic markers of CLL. In the meantime, we noticed that the expressions of TCF7, GMIP, SLAMF1, TNFRSF25, and LAG3 in CLL were different from those of healthy donors (p < 0.01). Moreover, the risk score and LAG3 level of matched pairs before and after treatment samples varied significantly. Finally, an interactive nomogram consisting of the nine-gene risk group and four clinical traits was established. The inhibitors of mTOR and cyclin-dependent kinases (CDKs) were considered effective in patients in the high-risk group according to the pRRophetic algorithm. Collectively, the SE-associated nine-gene prognostic model developed here may be used to predict the prognosis and assist in the risk stratification and treatment of CLL patients in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A possible link between the rs3025039C/T SNP and several cancer types has been reported, and the contribution of this polymorphism to oncogenesis has been investigated in several types of tumors [ 45 , 46 , 47 , 48 ]. In some cases, T allele was found associated to protection against cancer [ 27 , 49 ]. Allele T associated susceptibility has been reported for oral cancer [ 50 ], head and neck cancer [ 51 ], breast cancer [ 52 ] and colorectal cancer [ 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer

Scola

Bongiorno

Forte

et al. 2022

Genes

View full text Add to dashboard Cite

Differential genetically determined expression of transforming growth factor-β (TGF-β pathway and of vascular endothelial growth factor-A (VEGF-A) might modulate the molecular “milieu” involved in the etio-pathogenesis of non-melanoma skin cancer (NMSC). We have evaluated the frequency of some functionally relevant SNPs of TGF-β and VEGF-A genes in 70 NMSC patients and 161 healthy controls, typed for TGF-β1 rs1800471, TGF-β2 rs900, TGF-βR1 rs334348 and rs334349, TGF-βR2 rs4522809 and VEGF-A rs3025039 SNPs. TGF-βR2 rs1800629G allele and related genotypes were found to be associated with a possible protective role against NMSC, whereas VEGF-A rs3025039T was associated with an increased risk. To evaluate the effect of genotype combinations on NMSC susceptibility, we determined the frequencies of 31 pseudo-haplotypes due to non-random linkage among alleles of loci not lying on the same chromosome. Two pseudo-haplotypes that imply a minor allele of TGF-βR2 or minor allele of VEGF-A SNPs combined with major alleles of the other SNPs were, respectively, associated with a protective effect, and susceptibility to NMSC. In addition, a pseudo-haplotype involving minor alleles of TGF-β2 rs900, TGF-βR1 rs334348 and rs4522809 SNPs might be a susceptibility marker for NMSC. In conclusion, our data suggest that a complex interplay among the genetic polymorphisms of TGF-β, TGF-β receptors and VEGF-A genes might influence the net effect of genetic background of the patients on NMSC development. This might be relevant in the risk evaluation, diagnosis and treatment of NMSC.

show abstract

“…These promoter region polymorphisms (e.g., −1154 and −1498) modulate the VEGF transcription level by altering promoter activity and are associated with hepatocellular carcinoma [ 44 , 45 ]. Of the 3′-UTR polymorphisms (+936C>T, +1451C>T, +1612G>A, and +1725G>A), the +936C>T polymorphism is associated with diabetic retinopathy, polycystic ovarian syndrome, and certain types of cancer, such as glioma, leukemia, and breast cancer [ 46 , 47 , 48 , 49 , 50 ]. In Koreans specifically, the +1451C>T polymorphism is associated with colorectal cancer susceptibility [ 51 ] and the +1612G>A and +1725G>A polymorphisms are associated with recurrent pregnancy loss [ 52 ].…”

Section: Introductionmentioning

confidence: 99%

Study of the Association between VEGF Polymorphisms and the Risk of Coronary Artery Disease in Koreans

Kim

Lee

et al. 2022

JPM

View full text Add to dashboard Cite

Coronary artery disease (CAD), a leading cause of death worldwide, has a complex etiology comprising both traditional risk factors (type 2 diabetes, dyslipidemia, arterial hypertension, and cigarette smoking) and genetic factors. Vascular endothelial growth factor (VEGF) notably contributes to angiogenesis and endothelial homeostasis. However, little is known about the relationship between CAD and VEGF polymorphisms in Koreans. The aim of this study is to investigate the associations of 2 VEGF promoter region polymorphisms (−1154G>A [rs1570360], −1498T>C [rs833061]) and 4 VEGF 3′-UTR polymorphisms (+936C>T [rs3025039], +1451C>T [rs3025040], +1612G>A [rs10434], and +1725G>A [rs3025053]) with CAD susceptibility in Koreans. We studied 885 subjects: 463 CAD patients and 422 controls. Genotyping was conducted with polymerase chain reaction-restriction fragment length polymorphism analysis and TaqMan allelic discrimination assays, and the genotype frequencies were calculated. We then performed haplotype and genotype combination analyses and measured the associations between VEGF polymorphisms and clinical variables in both the CAD patients and control subjects. We detected statistically significant associations between CAD and certain VEGF allele combinations. In the haplotypes of 5 single-nucleotide polymorphisms, the VEGF allele combination −1154A/+936T was associated with a decreased prevalence of CAD (A-T-T-G-G of VEGF −1154G>A/−1498T>C/+936C>T/+1612G>A/+1725G>A, AOR = 0.077, p = 0.021). In contrast, the VEGF allele combinations −1498T/+1725A and −1498T/+1612A/+1725A were associated with an increased prevalence of CAD (G-T-C-C-A of VEGF −1154G>A/−1498T>C/+936C>T/+1451C>T/+1725G>A, AOR = 1.602, p = 0.047; T-C-C-A-A of VEGF −1498T>C/+936C>T/+1451C>T/+1612G>A/+1725G>A, AOR = 1.582, p = 0.045). Gene–environment combinatorial analysis showed that the combination of the VEGF +1725AA genotype and several clinical factors (e.g., body mass index, hemoglobin A1c, and low-density lipoprotein cholesterol) increased the risk of CAD. Therefore, we suggest that VEGF polymorphisms and clinical factors may impact CAD prevalence.

show abstract

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Cited by 3 publications

References 48 publications

Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients

Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients

TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer

Study of the Association between VEGF Polymorphisms and the Risk of Coronary Artery Disease in Koreans

Contact Info

Product

Resources

About